Phase 2 N=26 Hyperalgesia in Methadone-Maintained Patients: Can it be Treated?
Opioid-Induced Hyperalgesia
Primary: Change in Pain Threshold Time From Baseline to Week 5 — 2.95; -3.49 seconds
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=56 Dyspareunia and Central Sensitization
Endometriosis · Central Sensitisation · Dyspareunia
Primary: Deep Dyspareunia Score — 3.08 scores on a scale
Phase 3 N=140 Evaluation in the Treatment of Neuropathic Pain Post Breast Surgery
Breast Cancer Patient
Primary: Change in Neuropathic Pain Score at 2 Months (Numeric Rating Scale 0-10) — 4.1; 4.6 units on a scale
N/A N=8 Peripheral Sensory Input in Central Post Stroke Pain (CPSP)
Central Post Stroke Pain
Primary: Reduction in Spontaneous Pain Intensity After a Peripheral Nerve Block. — 6.5; 0.0 units on a scale
N/A N=22 Study on the Development of Opioid Induced Hyperalgesia (OIH) After Exposure to Alfentanil
Hyperalgesia
Primary: Pain Tolerance — 105.3; 19.2 seconds
N/A N=22 Nociceptive Pain Fiber Response
Painful Peripheral Diabetic Neuropathy
Primary: Changes in Small Nerve Fiber Density by Assessment of a Skin Biopsy Comparing Baseline to Day 60 — .1; .1 nerve fibers / mm squared
N/A N=86 Pregabalin for the Treatment of Pain After Posterior Spinal Fusions
Lumbar Spinal Fusions
Primary: Patient Controlled Analgesia (PCA) Hydromorphone Usage — 44; 39 mL
N/A N=50 Electrical Skin Conductance Monitoring as an Assessment of Post Operative Pain Scores
Postoperative Pain
Primary: Numeric Pain Rating Scale — 2.0; 2.7; 2.9 units on a scale
N/A N=28 Research Study to Determine Sensitivity to Gentle Touch and Pressure During an Active Migraine Attack.
Migraine
Primary: Proportion of Subjects With Allodynia During a Migraine Attack — 15 participants
N/A N=7 Opioid Taper Study
Chronic Pain
Primary: Pain Perception Measured Using the Cold-pressor Test (CPT) — 24.01; 42.02 seconds
N/A N=158 Central Nervous System Amplification in Lumbar Failed Back Surgery Syndrome
Chronic Pain
Primary: Clinical Pain Severity - 50% Reduction Responders vs Nonresponders — -83; 0 percentage of change
N/A N=7 Percutaneous Peripheral Nerve Stimulation (Neuromodulation) for Postoperative Analgesia
Postoperative Pain
Primary: Change From Baseline of Surgical Site Pain Level (NRS) at Rest [Percentage of Baseline Pain] — 64; 100; 55; 69 percentage of baseline
N/A N=31 Study To Assess The Reproducibility And Sensitivity Of Quantitative Sensory Testing In Patients With Neuropathic Pain
Neuropathic Pain
Primary: Mean Change From Baseline in Dynamic Allodynia Intensity at Visits 3 and 6 and Visits 4 and 7 — -1.09; -1.16; -1.31; -0.67 scores on a scale — p=0.7319
N/A N=26 Pregabalin in CIPN
Neuropathy · Pain
Primary: Change in Spontaneous Pain Intensity as a Function of Baseline MPT — -0.0179; -0.0172 Pearson correlation coefficient
Phase 4 N=20 Anti-CGRP for Inflammation and Pain Modulation in Small Fiber Neuropathy/Fibromyalgia
Trigeminal Neuralgia · Glossopharyngeal Neuralgia
Primary: Change in Pain Score — -0.6224; -1.005; -0.8102; -1.079 score on a scale
Phase 2 N=240 Prospective, Randomized Controlled Trial on Perioperative Pregabalin to Reduce Late-onset CRPS After TKA
CRPS
Primary: Epidural Medication Consumption Rate — 6.40; 5.77 mL/h — p=0.003
N/A N=93 Reduced Opioid Analgesic Requirements Via Improved Endogenous Opioid Function
Chronic Pain
Primary: Mean of the Change in Morphine Dosage (in mg) Required to Achieve 25% Reduction in Thermal Evoked Pain Responses Relative to Baseline (Pre-intervention) Placebo…
N/A N=38 Prevalence of Phonophobia and Cutaneous Allodynia in Episodic Migraineurs
Migraine
Primary: Correlation Between Phonophobia (Sound Sensitivity) and Allodynia (Skin Sensitivity) in Subjects With Episodic Migraine — 27; 6 participants — p=0.59
Phase 1 N=35 The Efficacy of MK-8291 in Participants With Post-herpetic Neuralgia (PHN) With Allodynia (MK-8291-012)
Postherpetic Neuralgia
Primary: Change From Baseline in Pain Intensity at Week 4 of Each Treatment Period — -1.776; -1.263 Score on a scale — p=0.075
Phase 4 N=368 P4 (Pregabalin for Peripheral Posttraumatic Pain)
Neuralgia
Primary: Weekly Mean Pain Score at End of Treatment (Week 8) From Daily Pain Diary — 4.61; 5.23 score on a scale — p=0.010
Phase 2 N=9 CC-10004 For The Treatment Of Vulvodynia
Vulvodynia
Primary: Global Response Assessment — 5 participants
N/A N=79 Effect of Ketamine on Opioid-Induced Hyperalgesia
Pain · Chronic Pain · Hyperalgesia
Primary: Change in Temperature of Pain Threshold — -0.02; -0.61; -0.61; -0.77 Degrees Celsius — p=0.274
N/A N=53 The Effect of Neurontin on Pain Management in the Acutely Burned Patient
Pain · Burn Injury
Primary: Opioid Consumption Between the Treatment and the Control Groups (Morphine Equivalents) — 7.0; 6.7 morphine equivalents — p=<0.05
Phase 4 N=421 Pain Increases After Shoulder Injection
Shoulder Pain
Primary: Incidence of a Flare Reaction — 44; 8; 149; 191 Person-visits
Early Phase 1 N=22 Developing Brain Stimulation as a Treatment for Chronic Pain in Opiate Dependent
Chronic Pain · Opiate Dependence · Lower Back Pain
Primary: Change in Quantitative Pain Testing Following Active TMS Compared to Baseline — 1.4; .3 Change from Baseline (degrees C) — p=.83
Phase 3 N=44 Brivaracetam to Reduce Neuropathic Pain in Chronic SCI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Spinal Cord Injuries · Neuropathic Pain
Primary: The International Spinal Cord Injury Pain Data Set (ISCIPBDS) (Version 2.0) - Change in Average Worst Neuropathic Pain Intensity — -0.5; -0.5 points
N/A N=92 Past Pain Experience and Perception of Experimental Pain
Schizophrenia · Major Depression
Primary: Visual Analog Scale Evaluation for the Pre-fixed Pressure Test — 2.8; 2.1; 1.2 units on a scale — p=0.121
N/A N=30 Subcutaneous Botulinum Toxin for Cutaneous Allodynia
Pain
Primary: Time Until Analgesic Failure — 76.3; 79 Days
N/A N=16 Postoperative Peripheral Nerve Stimulation for Management of Post-amputation Pain
Phantom Limb Pain · Postoperative Pain · Neuroma
Primary: Average Phantom Limb Pain (PLP) Score — 4.1; 3.1; 2.2; 3.0 score on a scale
Phase 2 N=79 Mechanistic Study of Duloxetine in Breast Cancer Patients With Chronic Pain
Pain
Primary: Change in Patient-reported Worst Pain Between Baseline and 5 Weeks of Treatment With Duloxetine — 6.54; 0.25; 4.06 score on a scale